TW202246315A

TW202246315A - 對冠狀病毒s蛋白具特異性之化合物及其用途

對冠狀病毒s蛋白具特異性之化合物及其用途 Download PDF

Info

Publication number: TW202246315A
Authority: TW; Taiwan
Prior art keywords: cov; antibody; antigen; binding fragment; sars
Prior art date: 2021-02-05

Application number

TW111104400A

Other languages

English (en)

Chinese (zh)

Inventor

蘿拉華可

Ｃ格禮特瑞帕佐

牧魯諾薩哈卡

蘿拉德瓦

承冀郭

Original Assignee

美商亞得捷歐治療公司

Priority date

2021-02-05

Filing date

2022-02-07

Publication date

2022-12-01

2022-02-07 Application filed by 美商亞得捷歐治療公司 filed Critical 美商亞得捷歐治療公司

2022-12-01 Publication of TW202246315A publication Critical patent/TW202246315A/zh

Links

241000711573 Coronaviridae Species 0.000 title claims abstract 19
150000001875 compounds Chemical class 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
239000000427 antigen Substances 0.000 claims abstract 83
102000036639 antigens Human genes 0.000 claims abstract 83
108091007433 antigens Proteins 0.000 claims abstract 83
239000012634 fragment Substances 0.000 claims abstract 77
241001678559 COVID-19 virus Species 0.000 claims abstract 20
241000315672 SARS coronavirus Species 0.000 claims abstract 20
238000000034 method Methods 0.000 claims abstract 20
102100031673 Corneodesmosin Human genes 0.000 claims abstract 9
101710139375 Corneodesmosin Proteins 0.000 claims abstract 9
229920001184 polypeptide Polymers 0.000 claims abstract 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract 2
102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 24
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 24
102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 24
101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 24
101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 24
125000003275 alpha amino acid group Chemical group 0.000 claims 24
241000004176 Alphacoronavirus Species 0.000 claims 15
229940049595 antibody-drug conjugate Drugs 0.000 claims 11
241000711467 Human coronavirus 229E Species 0.000 claims 10
241001109669 Human coronavirus HKU1 Species 0.000 claims 10
241000482741 Human coronavirus NL63 Species 0.000 claims 10
241001428935 Human coronavirus OC43 Species 0.000 claims 10
241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 8
-1 mechercharmycin Chemical compound 0.000 claims 8
101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims 6
101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 claims 6
206010035664 Pneumonia Diseases 0.000 claims 4
229940096437 Protein S Drugs 0.000 claims 4
101710198474 Spike protein Proteins 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
229940079593 drug Drugs 0.000 claims 4
239000003814 drug Substances 0.000 claims 4
MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 3
208000015181 infectious disease Diseases 0.000 claims 3
239000000203 mixture Substances 0.000 claims 3
108010059074 monomethylauristatin F Proteins 0.000 claims 3
208000024891 symptom Diseases 0.000 claims 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims 2
108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 2
TURXCFUGBPBPRS-UHFFFAOYSA-N Curvulin Chemical compound CCOC(=O)CC1=CC(O)=CC(O)=C1C(C)=O TURXCFUGBPBPRS-UHFFFAOYSA-N 0.000 claims 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
206010061598 Immunodeficiency Diseases 0.000 claims 2
102000015696 Interleukins Human genes 0.000 claims 2
108010063738 Interleukins Proteins 0.000 claims 2
241001467552 Mycobacterium bovis BCG Species 0.000 claims 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 claims 2
INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims 2
208000007536 Thrombosis Diseases 0.000 claims 2
IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
239000002253 acid Substances 0.000 claims 2
150000001413 amino acids Chemical class 0.000 claims 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
108010044540 auristatin Proteins 0.000 claims 2
230000001363 autoimmune Effects 0.000 claims 2
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 2
230000000747 cardiac effect Effects 0.000 claims 2
PZPPOCZWRGNKIR-PNVYSBBASA-N chaetocin Chemical compound N([C@@H]1N2C(=O)[C@]3(CO)SS[C@]2(C(N3C)=O)C2)C3=CC=CC=C3[C@]12[C@@]12C[C@]3(SS4)C(=O)N(C)[C@]4(CO)C(=O)N3[C@H]2NC2=CC=CC=C12 PZPPOCZWRGNKIR-PNVYSBBASA-N 0.000 claims 2
PZPPOCZWRGNKIR-UHFFFAOYSA-N chaetocin Natural products C1C2(C(N3C)=O)SSC3(CO)C(=O)N2C2NC3=CC=CC=C3C21C12CC3(SS4)C(=O)N(C)C4(CO)C(=O)N3C2NC2=CC=CC=C12 PZPPOCZWRGNKIR-UHFFFAOYSA-N 0.000 claims 2
230000001684 chronic effect Effects 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 2
206010014599 encephalitis Diseases 0.000 claims 2
230000028993 immune response Effects 0.000 claims 2
239000003112 inhibitor Substances 0.000 claims 2
108010093470 monomethyl auristatin E Proteins 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
230000002265 prevention Effects 0.000 claims 2
201000004193 respiratory failure Diseases 0.000 claims 2
LMXOHSDXUQEUSF-YECHIGJVSA-N sinefungin Chemical compound O[C@@H]1[C@H](O)[C@@H](C[C@H](CC[C@H](N)C(O)=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LMXOHSDXUQEUSF-YECHIGJVSA-N 0.000 claims 2
208000011580 syndromic disease Diseases 0.000 claims 2
NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 claims 1
MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 claims 1
MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 claims 1
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 claims 1
OMKSBDLWMROKNU-XYOKQWHBSA-N (3e)-3-[(2,5-dihydroxyphenyl)methylidene]-1h-indol-2-one Chemical compound OC1=CC=C(O)C(\C=C\2C3=CC=CC=C3NC/2=O)=C1 OMKSBDLWMROKNU-XYOKQWHBSA-N 0.000 claims 1
WILMROCKORZEMQ-AIUMZUNXSA-N (3e,5e,7e,9r,10r,11e,13e,17s,18s,20s)-20-[(r)-[(2r,3r,4s,5r,6r)-2,4-dihydroxy-6-[(2r)-2-[(2r,4s,5s,6s)-4-hydroxy-5-[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,6-dimethyloxan-2-yl]oxy-3-methoxypropyl]-3,5-dimethyloxan-2-yl]-hydroxymethyl]-10 Chemical compound O([C@@H]1/C=C/C(/C)=C/CC[C@H](O)[C@@H](OC)C[C@H](OC(=O)/C(C)=C/C(/C)=C/C(/C)=C/[C@H]1C)[C@@H](O)[C@@]1(O[C@@H]([C@@H]([C@H](O)[C@H]1C)C)C[C@H](COC)O[C@@H]1O[C@@H](C)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](OC)C2)[C@@](C)(O)C1)O)[C@@H]1O[C@@H](C)[C@H](OC)[C@@H](O)[C@@H]1O WILMROCKORZEMQ-AIUMZUNXSA-N 0.000 claims 1
SGYJGGKDGBXCNY-QXUYBEEESA-N (3s,9s,12r)-3-benzyl-6,6-dimethyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@@H]2C(=O)N1)=O)(C)C)CCCCC(=O)[C@@H]1CO1 SGYJGGKDGBXCNY-QXUYBEEESA-N 0.000 claims 1
MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 claims 1
MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 claims 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
CNTMOLDWXSVYKD-PSRNMDMQSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound OC(=O)C(/C)=C/[C@H](C(C)C)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC)C(C)(C)C1=CC=CC=C1 CNTMOLDWXSVYKD-PSRNMDMQSA-N 0.000 claims 1
MPGIDXBHXRMMSY-UHFFFAOYSA-N 1-(4,6-dipentyl-5,6-dihydrooxadiazin-2-yl)-3-hydroxypropan-1-one Chemical compound C(CCCC)C1=NN(OC(C1)CCCCC)C(CCO)=O MPGIDXBHXRMMSY-UHFFFAOYSA-N 0.000 claims 1
ISZXEMUWHQLLTC-LSIVYLFASA-N 2-[(2r,5s,6s)-6-[(2e,4e,6s)-7-[(2r,3r)-3-[(2r,3r,4r)-4-hydroxy-3-methoxypentan-2-yl]-2-methyloxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-5-methyloxan-2-yl]acetic acid Chemical compound CO[C@@H]([C@@H](C)O)[C@@H](C)[C@H]1O[C@]1(C)C[C@H](C)\C=C\C=C(/C)[C@@H]1[C@@H](C)CC[C@H](CC(O)=O)O1 ISZXEMUWHQLLTC-LSIVYLFASA-N 0.000 claims 1
IDCOTQWQVPRTNK-UHFFFAOYSA-N 2-n,6-n-bis[(4-methoxyphenyl)methyl]-9-propan-2-ylpurine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C(C)C)C2=N1 IDCOTQWQVPRTNK-UHFFFAOYSA-N 0.000 claims 1
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims 1
MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 claims 1
LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims 1
QZTWUDDGLIDXSE-UHFFFAOYSA-N 9-hydroxyellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 QZTWUDDGLIDXSE-UHFFFAOYSA-N 0.000 claims 1
239000005541 ACE inhibitor Substances 0.000 claims 1
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 1
208000030507 AIDS Diseases 0.000 claims 1
208000009304 Acute Kidney Injury Diseases 0.000 claims 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
BGYNLOSBKBOJJD-IUCAKERBSA-N Aeroplysinin 1 Chemical compound COC1=C(Br)[C@H](O)[C@](O)(CC#N)C=C1Br BGYNLOSBKBOJJD-IUCAKERBSA-N 0.000 claims 1
ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 claims 1
108010027164 Amanitins Proteins 0.000 claims 1
206010002199 Anaphylactic shock Diseases 0.000 claims 1
241000228212 Aspergillus Species 0.000 claims 1
208000035143 Bacterial infection Diseases 0.000 claims 1
208000014644 Brain disease Diseases 0.000 claims 1
208000011380 COVID-19–associated multisystem inflammatory syndrome in children Diseases 0.000 claims 1
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 1
206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
SGYJGGKDGBXCNY-UHFFFAOYSA-N Chlamydocin Natural products N1C(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(C)(C)NC(=O)C1CCCCCC(=O)C1CO1 SGYJGGKDGBXCNY-UHFFFAOYSA-N 0.000 claims 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
208000002330 Congenital Heart Defects Diseases 0.000 claims 1
206010010904 Convulsion Diseases 0.000 claims 1
KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims 1
LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 claims 1
CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 claims 1
SRUWWOSWHXIIIA-UKPGNTDSSA-N Cyanoginosin Chemical compound N1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](C)[C@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@H](C(O)=O)N(C)C(=O)[C@@H](C)[C@@H]1\C=C\C(\C)=C\[C@H](C)[C@@H](O)CC1=CC=CC=C1 SRUWWOSWHXIIIA-UKPGNTDSSA-N 0.000 claims 1
QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 claims 1
201000003883 Cystic fibrosis Diseases 0.000 claims 1
108010092160 Dactinomycin Proteins 0.000 claims 1
206010014522 Embolism venous Diseases 0.000 claims 1
208000032096 Encephalitic infection Diseases 0.000 claims 1
208000032274 Encephalopathy Diseases 0.000 claims 1
108010008165 Etanercept Proteins 0.000 claims 1
FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims 1
NJJDBBUWWOAOLD-UHFFFAOYSA-N Ferulenol Natural products C1=CC=C2OC(=O)C(CC=C(C)CCC=C(C)CCC=C(C)C)=C(O)C2=C1 NJJDBBUWWOAOLD-UHFFFAOYSA-N 0.000 claims 1
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
229930195518 Glucopiericidin Natural products 0.000 claims 1
108010026389 Gramicidin Proteins 0.000 claims 1
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
108010072471 HTI-286 Proteins 0.000 claims 1
208000010496 Heart Arrest Diseases 0.000 claims 1
206010019280 Heart failures Diseases 0.000 claims 1
208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
ISZXEMUWHQLLTC-UHFFFAOYSA-N Herboxidiene Natural products COC(C(C)O)C(C)C1OC1(C)CC(C)C=CC=C(C)C1C(C)CCC(CC(O)=O)O1 ISZXEMUWHQLLTC-UHFFFAOYSA-N 0.000 claims 1
UGIOXKVQFJIRMZ-UHFFFAOYSA-N Hygrolidin Natural products C1C(OC(=O)C=CC(O)=O)C(C)C(CC)OC1(O)C(C)C(O)C(C)C1C(OC)C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(C)C(=O)O1 UGIOXKVQFJIRMZ-UHFFFAOYSA-N 0.000 claims 1
206010020772 Hypertension Diseases 0.000 claims 1
229940124790 IL-6 inhibitor Drugs 0.000 claims 1
208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
208000029462 Immunodeficiency disease Diseases 0.000 claims 1
102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
208000032382 Ischaemic stroke Diseases 0.000 claims 1
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 claims 1
208000034800 Leukoencephalopathies Diseases 0.000 claims 1
206010067125 Liver injury Diseases 0.000 claims 1
MNASOWORUXKEPP-UHFFFAOYSA-N Microcolin B Natural products CCCCC(C)CC(C)C(=O)N(C)C(CC(C)C)C(=O)NC(C(C)OC(C)=O)C(=O)N(C)C(C(C)C)C(=O)N1CCCC1C(=O)N1C(=O)C=CC1C MNASOWORUXKEPP-UHFFFAOYSA-N 0.000 claims 1
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims 1
231100000678 Mycotoxin Toxicity 0.000 claims 1
208000009525 Myocarditis Diseases 0.000 claims 1
ZJZWZIXSGNFWQQ-UHFFFAOYSA-N N-[4-[[[4-(4-methoxyphenyl)-4-oxanyl]methylamino]-oxomethyl]phenyl]-2-furancarboxamide Chemical compound C1=CC(OC)=CC=C1C1(CNC(=O)C=2C=CC(NC(=O)C=3OC=CC=3)=CC=2)CCOCC1 ZJZWZIXSGNFWQQ-UHFFFAOYSA-N 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
208000008589 Obesity Diseases 0.000 claims 1
VYVUCONKFCPKEV-UHFFFAOYSA-N Okilactomycin Natural products CC1CCCC2C=C(C(C)CC23OC(=O)C4(C)C3CC(C(C)C1)C(=O)C4=O)C(=O)O VYVUCONKFCPKEV-UHFFFAOYSA-N 0.000 claims 1
206010053159 Organ failure Diseases 0.000 claims 1
206010033627 Pancreatic injury Diseases 0.000 claims 1
101800000891 Phallacidin Proteins 0.000 claims 1
108010009711 Phalloidine Proteins 0.000 claims 1
229930182661 Piericidin Natural products 0.000 claims 1
OWRCRVABZYJUES-UHFFFAOYSA-N Polyketomycin Natural products COC1=CC(=O)c2c(O)c3C(=O)C4(O)C(=O)C(=C(/C)O)C(=O)C(OC5CCC(OC6CC(C)(O)C(OC(=O)c7c(C)ccc(C)c7O)C(C)O6)C(C)O5)C4(O)Cc3c(C)c2C1=O OWRCRVABZYJUES-UHFFFAOYSA-N 0.000 claims 1
GZAYJWNDYQINEI-OBSDVKHNSA-N Pseurotin D Natural products CC[C@@H](O)C=C[C@H](O)C1=C(C)C(=O)[C@@]2(O1)[C@@H](O)[C@](NC2=O)(OC)C(=O)c3ccccc3 GZAYJWNDYQINEI-OBSDVKHNSA-N 0.000 claims 1
208000028017 Psychotic disease Diseases 0.000 claims 1
KIPSHYPQCJYONU-UHFFFAOYSA-N Quinaldopeptin Natural products CC1NC(=O)C2CCCCN2C(=O)CN(C)C(=O)CNC(=O)C2CCCCN2C(=O)C(NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)C(C)NC(=O)C2CCCCN2C(=O)CN(C)C(=O)CNC(=O)C2CCCCN2C(=O)C1NC(=O)C1=NC2=CC=CC=C2C=C1O KIPSHYPQCJYONU-UHFFFAOYSA-N 0.000 claims 1
QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 claims 1
208000033626 Renal failure acute Diseases 0.000 claims 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
XWNMORIHKRROGW-UHFFFAOYSA-N Ro 5-3335 Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CN1 XWNMORIHKRROGW-UHFFFAOYSA-N 0.000 claims 1
108091005774 SARS-CoV-2 proteins Proteins 0.000 claims 1
229930183496 Safracin Natural products 0.000 claims 1
229940122055 Serine protease inhibitor Drugs 0.000 claims 1
101710102218 Serine protease inhibitor Proteins 0.000 claims 1
206010049771 Shock haemorrhagic Diseases 0.000 claims 1
208000006011 Stroke Diseases 0.000 claims 1
108091033399 Telomestatin Proteins 0.000 claims 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
206010043784 Thyroiditis subacute Diseases 0.000 claims 1
FTGOWEQDZZMPNJ-GUMZKTDUSA-N Tolytoxin Chemical compound C([C@@]12[C@@H](OC)C[C@H]3O[C@@H](C=CC3)C[C@H]([C@@H](O)/C=C(\C)/C=C/C(=O)O[C@@H]([C@H]([C@H](OC)C[C@@H]2OC)C)[C@@H](C)[C@@H](O)[C@@H](C)CCC(=O)[C@H](C)[C@@H]([C@H](C)\C=C\N(C)C=O)OC)OC)O1 FTGOWEQDZZMPNJ-GUMZKTDUSA-N 0.000 claims 1
208000030886 Traumatic Brain injury Diseases 0.000 claims 1
DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
208000036142 Viral infection Diseases 0.000 claims 1
241000700605 Viruses Species 0.000 claims 1
PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 claims 1
MNASOWORUXKEPP-DEZPKOTESA-N [(2s,3s)-3-[[(2s)-2-[[(2r,4r)-2,4-dimethyloctanoyl]-methylamino]-4-methylpentanoyl]amino]-4-[methyl-[(2s)-3-methyl-1-[(2s)-2-[(2s)-2-methyl-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]amino]-4-oxobutan-2-yl] acetate Chemical compound CCCC[C@@H](C)C[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H]([C@H](C)OC(C)=O)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1C(=O)C=C[C@@H]1C MNASOWORUXKEPP-DEZPKOTESA-N 0.000 claims 1
UNPSMUMJWYZQHC-CYVBNFEDSA-N [(3r,5s,6r,7s,8e,10s,11s,12z,14e)-21-[3-(dimethylamino)propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCCN(C)C)C(=O)C=C1C2=O UNPSMUMJWYZQHC-CYVBNFEDSA-N 0.000 claims 1
230000002159 abnormal effect Effects 0.000 claims 1
230000005856 abnormality Effects 0.000 claims 1
229930183665 actinomycin Natural products 0.000 claims 1
230000001154 acute effect Effects 0.000 claims 1
201000011040 acute kidney failure Diseases 0.000 claims 1
231100000439 acute liver injury Toxicity 0.000 claims 1
206010000891 acute myocardial infarction Diseases 0.000 claims 1
206010001053 acute respiratory failure Diseases 0.000 claims 1
229960002964 adalimumab Drugs 0.000 claims 1
201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
230000002411 adverse Effects 0.000 claims 1
QZBCDLLHQSDFIG-ZEVBXJOLSA-N agrochelin Chemical compound CCCCCC1=CC=CC(O)=C1C1=N[C@@H]([C@H]2N([C@H]([C@@H](O)C(C)(C)C(O)=O)CS2)C)CS1 QZBCDLLHQSDFIG-ZEVBXJOLSA-N 0.000 claims 1
QZBCDLLHQSDFIG-UHFFFAOYSA-N agrochelin Natural products CCCCCc1cccc(O)c1C1=NC(CS1)C1SCC(C(O)C(C)(C)C(O)=O)N1C QZBCDLLHQSDFIG-UHFFFAOYSA-N 0.000 claims 1
SSNQAUBBJYCSMY-UHFFFAOYSA-N aigialomycin A Natural products C12OC2CC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=CC(OC)=CC=2O SSNQAUBBJYCSMY-UHFFFAOYSA-N 0.000 claims 1
CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims 1
208000003455 anaphylaxis Diseases 0.000 claims 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
230000009517 anoxic brain damage Effects 0.000 claims 1
230000000507 anthelmentic effect Effects 0.000 claims 1
229940124339 anthelmintic agent Drugs 0.000 claims 1
239000000921 anthelmintic agent Substances 0.000 claims 1
230000000844 anti-bacterial effect Effects 0.000 claims 1
229940124599 anti-inflammatory drug Drugs 0.000 claims 1
239000000611 antibody drug conjugate Substances 0.000 claims 1
229940125715 antihistaminic agent Drugs 0.000 claims 1
239000000739 antihistaminic agent Substances 0.000 claims 1
239000003096 antiparasitic agent Substances 0.000 claims 1
239000003443 antiviral agent Substances 0.000 claims 1
NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 claims 1
SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 claims 1
WILMROCKORZEMQ-UHFFFAOYSA-N apoptolidin Natural products C1C(C)(O)C(OC2OC(C)C(O)C(OC)C2)C(C)OC1OC(COC)CC(C(C(O)C1C)C)OC1(O)C(O)C(OC(=O)C(C)=CC(C)=CC(C)=CC1C)CC(OC)C(O)CCC=C(C)C=CC1OC1OC(C)C(OC)C(O)C1O WILMROCKORZEMQ-UHFFFAOYSA-N 0.000 claims 1
208000006673 asthma Diseases 0.000 claims 1
229960003159 atovaquone Drugs 0.000 claims 1
KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
229930192649 bafilomycin Natural products 0.000 claims 1
XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 claims 1
YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 1
229960002071 bepotastine Drugs 0.000 claims 1
230000000903 blocking effect Effects 0.000 claims 1
210000001185 bone marrow Anatomy 0.000 claims 1
206010006451 bronchitis Diseases 0.000 claims 1
229930195731 calicheamicin Natural products 0.000 claims 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
229930191237 chaetoglobosin Natural products 0.000 claims 1
PRSOPHSUKXJKIM-CFBAGHHKSA-N chembl174839 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(O)OC2=C1 PRSOPHSUKXJKIM-CFBAGHHKSA-N 0.000 claims 1
KIPSHYPQCJYONU-GVPFWXHKSA-N chembl1994663 Chemical compound N([C@@H](C(C(=O)N1CCCC[C@H]1C(=O)NCC(=O)N(C)CC(=O)N1CCCCC1C(=O)N[C@@H]1C)NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)C)C(=O)C2CCCCN2C(=O)CN(C)C(=O)CNC(=O)C2CCCCN2C(=O)[C@H]1NC(=O)C1=NC2=CC=CC=C2C=C1O KIPSHYPQCJYONU-GVPFWXHKSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
238000002512 chemotherapy Methods 0.000 claims 1
108700023145 chlamydocin Proteins 0.000 claims 1
229960003677 chloroquine Drugs 0.000 claims 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
229960003728 ciclesonide Drugs 0.000 claims 1
229950001565 clazakizumab Drugs 0.000 claims 1
229960001338 colchicine Drugs 0.000 claims 1
LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
230000000295 complement effect Effects 0.000 claims 1
230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 1
208000028831 congenital heart disease Diseases 0.000 claims 1
OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims 1
OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims 1
239000003246 corticosteroid Substances 0.000 claims 1
229960001334 corticosteroids Drugs 0.000 claims 1
150000001904 cucurbitacins Chemical class 0.000 claims 1
QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 claims 1
231100000433 cytotoxic Toxicity 0.000 claims 1
230000001472 cytotoxic effect Effects 0.000 claims 1
229960005107 darunavir Drugs 0.000 claims 1
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
229960000975 daunorubicin Drugs 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 claims 1
229940120889 dipyrone Drugs 0.000 claims 1
208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
229930188854 dolastatin Natural products 0.000 claims 1
229960004679 doxorubicin Drugs 0.000 claims 1
229960005501 duocarmycin Drugs 0.000 claims 1
VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
229930184221 duocarmycin Natural products 0.000 claims 1
230000002526 effect on cardiovascular system Effects 0.000 claims 1
239000012636 effector Substances 0.000 claims 1
201000002491 encephalomyelitis Diseases 0.000 claims 1
229930185143 englerin Natural products 0.000 claims 1
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
229930013356 epothilone Natural products 0.000 claims 1
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
150000003883 epothilone derivatives Chemical class 0.000 claims 1
229960000403 etanercept Drugs 0.000 claims 1
229950008454 favipiravir Drugs 0.000 claims 1
ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 1
230000003176 fibrotic effect Effects 0.000 claims 1
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 claims 1
229960000936 fumagillin Drugs 0.000 claims 1
230000002496 gastric effect Effects 0.000 claims 1
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
230000013595 glycosylation Effects 0.000 claims 1
238000006206 glycosylation reaction Methods 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
229960004171 hydroxychloroquine Drugs 0.000 claims 1
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
GEZBIZMDLMTFDB-KJKHOEIASA-N hygrolidin Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(C)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C)[C@H](C)[C@H](OC(=O)\C=C\C(O)=O)C1 GEZBIZMDLMTFDB-KJKHOEIASA-N 0.000 claims 1
SSNQAUBBJYCSMY-KNTMUCJRSA-N hypothemycin Chemical compound O([C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)C[C@H]1O[C@@H]11)C(=O)C=2C1=CC(OC)=CC=2O SSNQAUBBJYCSMY-KNTMUCJRSA-N 0.000 claims 1
230000002519 immonomodulatory effect Effects 0.000 claims 1
230000007813 immunodeficiency Effects 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
229940124589 immunosuppressive drug Drugs 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
102000002467 interleukin receptors Human genes 0.000 claims 1
108010093036 interleukin receptors Proteins 0.000 claims 1
208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
229960002418 ivermectin Drugs 0.000 claims 1
229960002014 ixabepilone Drugs 0.000 claims 1
FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 1
DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 claims 1
230000007774 longterm Effects 0.000 claims 1
229960004525 lopinavir Drugs 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
WWNXYRCJJRRWAQ-ALCXHWRFSA-N mensacarcin Chemical compound O=C([C@@]1(O)[C@H](O)[C@]23O[C@]3([C@@H]([C@@H]1C)O)C(=O)C1=CC=CC(OC)=C1[C@@H]2OC)[C@@H]1O[C@H]1C WWNXYRCJJRRWAQ-ALCXHWRFSA-N 0.000 claims 1
ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 1
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims 1
229960000485 methotrexate Drugs 0.000 claims 1
HIMMZWQWBNOPJH-UHFFFAOYSA-N methyl 4-[4-(dimethylamino)-6-methyl-5-[6-methyl-5-[(6-methyl-5-oxo-2h-pyran-2-yl)oxy]oxan-2-yl]oxyoxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate Chemical compound C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CCC1OC1OC(C)C(=O)C=C1 HIMMZWQWBNOPJH-UHFFFAOYSA-N 0.000 claims 1
108010032420 microcolin B Proteins 0.000 claims 1
108010067094 microcystin Proteins 0.000 claims 1
229960004857 mitomycin Drugs 0.000 claims 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
229960001156 mitoxantrone Drugs 0.000 claims 1
229960005170 moexipril Drugs 0.000 claims 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
108010074166 muscotoxin A Proteins 0.000 claims 1
230000035772 mutation Effects 0.000 claims 1
239000002636 mycotoxin Substances 0.000 claims 1
208000037891 myocardial injury Diseases 0.000 claims 1
CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 claims 1
MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 claims 1
229950009865 nafamostat Drugs 0.000 claims 1
230000002956 necrotizing effect Effects 0.000 claims 1
229960000884 nelfinavir Drugs 0.000 claims 1
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 1
CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 claims 1
229950010159 nemorubicin Drugs 0.000 claims 1
235000020824 obesity Nutrition 0.000 claims 1
KQZIMLFKBWIOJJ-CHNXQSITSA-N okilactomycin Chemical compound C[C@H]1C[C@@H](C)CCC[C@@H]2C=C(C(O)=O)[C@H](C)C[C@]32OC(=O)[C@]2(C)C(=O)C(=C)[C@H]1O[C@H]32 KQZIMLFKBWIOJJ-CHNXQSITSA-N 0.000 claims 1
229930191479 oligomycin Natural products 0.000 claims 1
MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 claims 1
210000000056 organ Anatomy 0.000 claims 1
KUBDTFZQCYLLGC-VZORSVKHSA-N phallacidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KUBDTFZQCYLLGC-VZORSVKHSA-N 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
BBLGCDSLCDDALX-LKGBESRRSA-N piericidin A Chemical compound COC=1NC(C\C=C(/C)C\C=C\C(\C)=C\[C@@H](C)[C@@H](O)C(\C)=C\C)=C(C)C(=O)C=1OC BBLGCDSLCDDALX-LKGBESRRSA-N 0.000 claims 1
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
229960001237 podophyllotoxin Drugs 0.000 claims 1
YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 1
OWRCRVABZYJUES-FLJLGRLJSA-N polyketomycin Polymers O([C@H]1[C@](C)(O)C[C@@H](O[C@H]1C)O[C@H]1CC[C@@H](O[C@@H]1C)O[C@@H]1C(=O)C(=C(/C)O)/C(=O)[C@@]2(O)C(=O)C=3C(O)=C4C(=O)C=C(C(C4=C(C)C=3C[C@]21O)=O)OC)C(=O)C1=C(C)C=CC(C)=C1O OWRCRVABZYJUES-FLJLGRLJSA-N 0.000 claims 1
208000022076 postinfectious encephalitis Diseases 0.000 claims 1
230000035935 pregnancy Effects 0.000 claims 1
230000037452 priming Effects 0.000 claims 1
229930192291 pseurotin Natural products 0.000 claims 1
SLYDIPAXCVVRNY-UOWMTANKSA-N pseurotin A Chemical compound O1C([C@@H](O)[C@@H](O)\C=C/CC)=C(C)C(=O)[C@]21C(=O)N[C@](C(=O)C=1C=CC=CC=1)(OC)[C@@H]2O SLYDIPAXCVVRNY-UOWMTANKSA-N 0.000 claims 1
YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
108700023331 quinaldopeptin Proteins 0.000 claims 1
229960005567 rebeccamycin Drugs 0.000 claims 1
INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 claims 1
108020003175 receptors Proteins 0.000 claims 1
102000005962 receptors Human genes 0.000 claims 1
230000002829 reductive effect Effects 0.000 claims 1
RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims 1
RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
230000002441 reversible effect Effects 0.000 claims 1
230000033764 rhythmic process Effects 0.000 claims 1
229960000311 ritonavir Drugs 0.000 claims 1
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
108700026174 sandramycin Proteins 0.000 claims 1
WXIVYIYCEBUEHL-RTQGILJWSA-N sandramycin Chemical compound C([C@H](C(=O)N1CCCC[C@H]1C(=O)NCC(=O)N(C)CC(=O)N(C)[C@H](C(OC1)=O)C(C)C)NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)CNC(=O)[C@@H]2CCCCN2C(=O)[C@@H]1NC(=O)C1=NC2=CC=CC=C2C=C1O WXIVYIYCEBUEHL-RTQGILJWSA-N 0.000 claims 1
229940084560 sanguinarine Drugs 0.000 claims 1
YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims 1
229960001852 saquinavir Drugs 0.000 claims 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 1
239000003001 serine protease inhibitor Substances 0.000 claims 1
230000035939 shock Effects 0.000 claims 1
229950008974 sinefungin Drugs 0.000 claims 1
230000000391 smoking effect Effects 0.000 claims 1
208000005809 status epilepticus Diseases 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
201000007497 subacute thyroiditis Diseases 0.000 claims 1
229950009150 taltobulin Drugs 0.000 claims 1
YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 claims 1
201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
238000002054 transplantation Methods 0.000 claims 1
230000009529 traumatic brain injury Effects 0.000 claims 1
YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims 1
229960002109 tuberculosis vaccine Drugs 0.000 claims 1
229930184737 tubulysin Natural products 0.000 claims 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
229960005486 vaccine Drugs 0.000 claims 1
ZWCXYZRRTRDGQE-LUPIJMBPSA-N valyl gramicidin a Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-LUPIJMBPSA-N 0.000 claims 1
208000004043 venous thromboembolism Diseases 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1
230000003442 weekly effect Effects 0.000 claims 1
JFCFGYGEYRIEBE-YVLHJLIDSA-N wob38vs2ni Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 JFCFGYGEYRIEBE-YVLHJLIDSA-N 0.000 claims 1
230000009286 beneficial effect Effects 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000006386 neutralization reaction Methods 0.000 abstract 1
230000003472 neutralizing effect Effects 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1